glp-1 long term use The unknown trajectory of long term side effects of

Description

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were developed as insulinotropic and anti-hyperglycemic agents for the treatment of type 2 diabetes, but...

These medications are well-known for their use in the treatment of diabetes and obesity due to the way they lower blood sugar levels, however, you may not know that our bodies release []

The two incretin peptides that enable this effect are the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide 1 (GLP-1), which ...

The two most important incretin hormones responsible for this effect are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1

Liraglutide (3.0 mg, daily subcutaneous injection, n=22) or semaglutide (1.0 mg, weekly subcutaneous injection, n=18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%